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Abstract
Treatment for advanced ovarian cancer is rarely curative; three quarters of patients with advanced disease relapse
and ultimately die with resistant disease. Improving patient outcomes will require the introduction of new treatments
and better patient selection. Abrogations in the DNA damage response (DDR) may allow such stratifications.
A defective DNA-damage response (DDR) is a defining hallmark of high grade serous ovarian cancer (HGSOC). Indeed,
current evidence indicates that all HGSOCs harbour a defect in at least one major DDR pathway. However, defective
DDR is not mediated through a single mechanism but rather results from a variety of (epi)genetic lesions affecting one
or more of the five major DNA repair pathways. Understanding the relationship between these pathways and how
these are abrogated will be necessary in order to facilitate appropriate selection of both existing and novel agents.
Here we review the current understanding of the DDR with regard to ovarian, and particularly high grade serous,
cancer, with reference to existing and emerging treatments as appropriate.
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Background
Epithelial ovarian cancer is not one homogenous disease,
but a collection of disparate cancers arising from differ-
ent tissues, including the fallopian tube and the ovary,
each of which represents a very different biological en-
tity. Current evidence suggests five major subtypes of
epithelial ovarian cancer, namely, high grade serous, low
grade serous, endometrioid, clear cell and mucinous
cancers, of which high grade serous is the commonest.
Teasing out the heterogeneity between these types is of
major importance but remains a challenge. Understanding
is hampered by the relative lack of driver mutations and the
massive genetic instability that characterises many forms of
the disease and makes molecular profiling difficult.
Genomic and transcriptomic studies have managed to
identify a limited number of driver mutations, restricted
at present largely to p53 and BRCA1/2, but have grossly
failed to identify predictive patterns that can be used to
determine therapy. A notable exception is the identifica-
tion of defective homologous recombination as a pre-
dictor of response to both platinum [1] and PARP
inhibitor therapy [2].Building upon this, and using de-
fects in other DNA damage repair (DDR) mechanisms
as a stratification tool, has enormous potential. The in-
ability to repair DNA damage is one of the hallmarks of
the cancer cell, however rendering a cell defective in
DNA damage repair is not mediated through a single
process, rather it is conferred by a wide variety of gen-
omic defects and this can result in differing sensitivities
to conventional and novel chemotherapeutic agents.
In general, DNA damage results in either single strand
or double strand breaks. Current understanding suggests
that there are five mechanisms used by mammalian cells
to identify and repair DNA damage. These are mismatch
repair (MMR), base excision repair (BER), and nucleotide
excision repair (NER) for single strand breaks and hom-
ologous recombination (HR) and non homologous end
joining (NHEJ) for double strand breaks (see Fig. 1). Single
strand breaks may be repaired directly but if left unre-
paired will result in a stalled replication fork. Replication
stress is the term coined to describe the effects on the cell
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of a stalled replication fork. Replication stress should acti-
vate functional DNA checkpoint proteins to trigger the
commencement of the double strand DNA repair path-
ways. However, in cancer cells the combination of a high
replication rate and defective DNA repair mechanisms
can lead instead to genomic instability. This is particularly
the case in high grade serous ovarian cancer which is
characterised by genomic instability. Given the high levels
of genomic instability and subsequent chromosomal rear-
rangements which are tolerated by high grade serous can-
cer cells in particular, it is highly likely that at least one of
these five pathways is dysfunctional in each cell (Table 1).
Through the understanding of these DNA repair mech-
anisms, their interaction and how they may be defective in
women with different subtypes of EOC, it may be possible
to target chemotherapy to the molecular mechanisms
underlying a cancer. Synthetic lethality is the term coined
to describe the effect of the combination of two genetic al-
terations that are lethal to cells, but alone do not have a
negative effect (reviewed by Kaelin [3]). Discovery of novel
drugs which exploit synthetic lethality is one such way
that the understanding of defective DNA repair mecha-
nisms can advance the management of ovarian cancer.
Treatments exploit the exquisite balance of DNA dam-
age in a cancer cell by either inducing further DNA
damage, with which the cell’s already impaired DNA
capacity cannot cope, or by impairing the capacity of the
DDR even further. Either strategy leads to catastrophic
DNA damage causing cell death. The benefit of the lat-
ter approach in which DDR pathways are inhibited in
the cell, is that it has little effect on normal cells which
include many overlapping pathways that can cope with
loss of a single pathway. Thus the toxicity of these tar-
geted treatments is often more acceptable than conven-
tional cytotoxic chemotherapy.
Here we review the current state of knowledge regard-
ing the role of the various DNA repair pathways in ovar-
ian cancer; using high grade serous cancer as the
exemplar, but referring to the other subtypes where
appropriate.
Fig. 1 The phases of the cell cycle and DNA repair mechanisms active during the four stages. Both classical and alternative non homologous end
joining (C-NHEJ and A-NHEJ) repair double strand breaks and are active throughout the cell cycle, they are especially active in G1 [25]. Base
excision repair (BER) removes damaged nucleotides and repairs single strand breaks throughout the cell cycle [60]. Nucleotide excision repair is
concerned with the removal of bulky damaged DNA lesions and single strand breaks during G1. Mismatch repair corrects DNA mismatches and
repairs single strand breaks during S phase [91]. Homologous recombination repairs double strand breaks during S phase and G2 [4]
Table 1 The known contribution of defective DNA repair pathways to ovarian cancer
DNA repair pathway Type of repair Contribution to serous
ovarian cancer
Contribution to all histological
subtypes of ovarian cancer
Homologous Recombination Double Strand Breaks 50% [4] 50%
Non Homologous Enjoining Double Strand Breaks
Base Excision Repair Nucleotide Excision and Single
Strand Breaks
Polymorphisms and altered expression
of BER components in 63–67% ovarian
cancers [60, 91]
Mismatch Repair Single Strand Breaks, Nucleotide
Mismatches
0.18% [94] 0.76% [94], mostly clear cell
Nucleotide Excision Repair Single Strand Breaks, Bulky Lesions 8%
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Homologous recombination
Mechanism
Homologous recombination (HR) is a high fidelity
mechanism for repairing double strand breaks or stalled
replication forks that occur during S and G2 phases of
the cell cycle [4]. DSBs can be caused by ionising radi-
ation, reactive oxygen species and antineoplastic drugs,
such as anthracyclines and bleomycin. Inability to repair
DSB causes chromosomal rearrangements and can lead
to cell death [4].
HR uses the sister chromatid as a template to repair
the DSB. The damaged DNA ends of the DSB are
resected by the RAD50, MRE11 and NBS1 complex (me-
diated by BRCA1). The complex, using a 3′-5′ exonucle-
ase exposes the 3′ strand ends on either side of the DSB
[5]. Single strand DNA is unwound and the 3′ strand
from the damaged chromosome invades into the sister
chromosome, at the complementary sequence, using
BRCA2 and the single strand binding protein RAD51.
DNA polymerase then reads off the complimentary se-
quence to extend the previously damaged 3′ end. The
replication continues past the original DSB and con-
tinues to the end of the chromosome (see Fig. 2) [6].
It has been estimated that there are at least 40 proteins
participating in this pathway, but it was the recognition that
this included BRCA1 and BRCA2 that provided the stimu-
lus to study this pathway in breast and ovarian cancer.
The role of homologous recombination in high grade
serous ovarian Cancer
Overall, defects in HR, whether through mutation or
epigenetic silencing of key proteins, have been found in
up to 50% EOC [1, 7].
BRCA1 and 2
Mutations in BRCA1 and BRCA2 are well documented
in hereditary ovarian cancer syndromes. As a result of
carrying mutations in BRCA1 and BRCA2 women carry
a 40% lifetime risk of epithelial ovarian cancer [8].
BRCA1 and 2 dysfunction is also prevalent in sporadic
epithelial ovarian cancer [9]. The term “BRCAness”, which
is synonymous with defective homologous recombination
(HRD), has been coined to describe the phenotype of dys-
functional BRCA1 and 2, brought about by epigenetic si-
lencing. Mechanisms contributing to HRD in sporadic
EOC include BRCA1 hypermethylation, occurring in 5–
31% of sporadic ovarian cancer [10, 11]. Estimates of the
prevalence of BRCA1 and 2 mutations in the general
population range from 1 in 400 to 1 in 800 [12].
Of the histological subtypes of EOC, high grade serous
EOC is associated with a BRCA1/2 mutations of 10.9
and 5.6% respectively, whilst endometrioid EOC is asso-
ciated with a 2.1% mutation rate [13]. BRCA1 and 2 do
not appear to play a role in mucinous EOC.
Implications for therapy
Defective HR allows accumulation of mutations thereby
promoting oncogenesis, but appears to also confer a prog-
nostic advantage, possibly through improved sensitivity to
chemotherapeutic agents and ionising radiation [14, 15].
This effect is not limited just to BRCA related cancers
and it is now clear that all HR defective tumours, identi-
fied using a RAD51 immunoflourescence assay, are associ-
ated with improved survival compared to HR competent
tumours when managed with platinum based chemother-
apy [1].
Therefore, disruption of functional HR is a potential
therapeutic target to prevent chemotherapy resistance. A
clinical example, although with little current clinical to
support it, is the use of the BCR-ABL inhibitor, Imatinib.
RAD51 requires phosphorylation in order to become ac-
tive during the process of homologous recombination and
Fig. 2 Double Strand Break (DSB) repair by Homologous Recombination.
When a DSB is recognised, BRCA1 mediates the recruitment of the MRN
complex, which comprises MRE11, RAD50 and NBS1 [3]. The MRN
complex recruits ataxia-telangiectasia mutated (ATM) which, in turn,
activates MRN components by phosphorylating them. The MRN complex
work with CtIP and EXO1 to resect 3′ ends of the DS. Replication protein
A (RPA) covers the DNA overhang to prevent it from being degraded.
This stage of HR, nucleolytic processing, can be defunct in hereditary
ovarian cancer; a single base mutation in exon 10 of MRE11 is reported in
hereditary ovarian cancers [92] and RAD50 protein truncation is reported
in hereditary breast and ovarian cancer families. As well as
activating nucleolytic processing machinery, ATM phosphorylates
and activates BRCA1 and RAD51. ATM is mutated in 2% of high
grade EOC [7] and is significantly associated with platinum resistance
[41]. Single strand DNA is unwound and the damaged chromosome
invades the sister chromosome to form a Holliday junction. This occurs
when RPA is replaced by RAD51, facilitated by BRCA2, allowing for
strand invasion [93]. RAD51 is hypermethylated in 3% of high grade
serous EOC, resulting in ineffective strand invasion [7]. MSY (not
shown) is an oncogene that can silence the activation domain of
BRCA2 it is overexpressed in 17% sporadic high grade serous ovarian
cancer [15]
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phosphorylation is dependent on the proto-oncogene
ABL1. Thereby using Imatinib, HR is inhibited and cells
are sensitised to crosslinking chemotherapy agents and
ionising radiation [16].
PARP inhibitors
Since the landmark papers of Bryant and Farmer [17, 18],
the therapeutic effect of PARP inhibition has been pre-
sumed to be mediated via the inhibition of the base exci-
sion repair pathway in cells already defective in
homologous recombination. The concept of HR/BER syn-
thetic lethality is based upon the idea that most single
strand breaks would be repaired by BER, if this is inhibited
by PARPi then they persist to become stalled replication
forks during replication which then cannot be repaired by
the defective HR in the cell.
PARP inhibitors have shown clinical efficacy in tu-
mours with defective HR. The PARPi, olaparib, has
shown efficacy in both the relapsed setting, in women
with BRCA1/2 mutations and ovarian cancer [19], and
when used as maintenance therapy in women with spor-
adic high grade serous ovarian cancer, improving
progression-free survival time, when compared to pla-
cebo [20]. However the remaining challenge is to iden-
tify HR defective tumours; in a recent phase III study of
niraparib, which demonstrated efficacy in women with
platinum sensitive relapse, the greatest effect was, not
surprisingly, seen in tumours with a germline BRCA
mutation but the test used to determine HR status in
the non BRCA related tumours failed to provide a clinic-
ally useful stratification [21].
Other HR related targets
Whilst PARP inhibitors have clear clinical utility and
serve as a great example of synthetic lethality, there are
other opportunities to target HR related proteins includ-
ing ATR.
ATR is a potential target as it works upstream in the
HR process and is influential over the whole pathway.
ATR initiates HR in response to radiation or platinum
induced stalled replication forks and ATR inhibition
should render the cell defective for HR [22]. NU6027
has been shown to inhibit ATR in preclinical studies and
has been found to enhance hydroxyurea and cisplatin
cytotoxicity, inhibit RAD51 focus formation, and lead to
cell cycle arrest at G2/M. Further, when used with
PARPi or cells with defective XRCC1, NU6027 demon-
strates synthetic lethality [23].Two ATR inhibitors,
VX-970 (similar to VE-821) and AZD-6738, are cur-
rently undergoing clinical evaluation. VX-970 is being
evaluated both as a single agent and in combination with
platinum-based chemotherapy (clinicaltrials.gov identi-
fier: NCT02157792) and AZD-6738 in haematological
malignancies with 11q deletions (ATM defective) (clini-
caltrials.gov identifier: NCT01955668).
A further way to block HR is to inhibit CDK1, which ac-
tivates BRCA1. Preclinical studies showed that CDK1 in-
hibitor AG024322 is synthetically lethal with PARPi [24].
Non homologous End Joining
Mechanism
Non homologous end joining (NHEJ), the other pathway
in the repair of DNA DSBs, has received less attention
than HR as a determinant of response to therapy. Emer-
ging evidence suggests that this may be a serious oversight
and that NHEJ may have a major role in determining out-
come to treatment. NHEJ occurs during G0 and G1 of the
cell cycle, with some activity in late S and G2 [25] and is
considered to be responsible for the majority of DSB re-
pairs caused by ionising radiation [26].
NHEJ has always been considered to be an error prone
process relying on modification of DNA breaks to allow
joining (or synapsis), rather than directly replicating the
sister chromatid [27]. Whilst it is not entirely clear why
cells choose one pathway over the other it has been
hypothesised that higher eukaryotes use the error prone
NHEJ more than HR because NHEJ allows for faster
DNA repair during a dynamic cell cycle and does not
have the same steric constraints as HR, where the sister
chromatid needs to be in close proximity [25, 28]. The
NHEJ process comprises two pathways, a classical and
an alternative pathway [29].
The classical NHEJ pathway
The classical, canonical, or DNA-PK dependent path-
way, is active in normally functioning cells and occurs in
the absence of a DNA template or extended regions of
microhomology. The classical pathway is inherently ac-
curate but is adaptable and therefore infidelity can creep
into the process as a result of the nature of the damage
that requires repair [30].
Classical NHEJ involves the actions of 6 key proteins:
DNA-PKcs, the Ku70/Ku80 heterodimer, Artemis, DNA
ligase IV, XRCC4 and XLF [29].
Ku (Ku70/Ku80 heterodimer), a ring like structure,
binds to the DNA DSB with high affinity and recruits
the serine-threonine protein kinase DNA-PK. Ku is able
to stabilise DNA-PK’s affinity for the DNA terminus [31]
and may act as a docking site for other proteins in
NHEJ. If the ends of the DNA DSB are not compatible
then ‘overhangs’ of DNA need to be removed, trimmed
back to a microhomology and resynthesized by nucleases
and DNA polymerases such as Artemis. Artemis can
form both a 3′ and a 5′ endonuclease when complexed
with DNA-PK [32]. Once the ends are compatible they
can be ligated. DNA ligase IV and XRCC4 co-factor,
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along with XLF appear to be responsible in humans for
this ligation in NHEJ [33, 34].
The alternative NHEJ (A-EJ) pathway
The alternative, (also known as the back up or microho-
mology mediated end joining) pathway is less well char-
acterised than the classical pathway. As the name
suggests, it has been found to be active when other
mechanisms, (classical NHEJ and HR) are inhibited or
absent. It can be activated throughout the cell cycle and
is slower than the classical pathway [35]. A-EJ pathway
is independent of Ku and frequently uses microhomolo-
gies distant from the DSB. A-EJ is typically associated
with deletions at the repair junction and therefore is
highly mutagenic. The key proteins proposed to be ac-
tive in the alternative pathway are PARP1, DNA ligase
III and XRCC1 and thought to be promoted by DNA
polymerase Θ [36]. PARP1 recognises and binds to DNA
at DSB in competition with Ku to fulfil a similar role
[37]. XRCC1 and LIG III form a complex to ligate the
broken DSB strands [38].
Ku is biochemically more competitive than PARP1, how-
ever in cells that are Ku80 deficient, inhibiting PARP results
in both arms of NHEJ being defective, resulting in the cell
being sensitive to the effects of ionising radiation [39].
Role in high grade serous epithelial ovarian Cancer
Errors in NHEJ are associated with therapeutic resist-
ance. Defective NHEJ has been found in up to 50% of
ovarian cancers, is independent of HR function and ap-
pears to confer resistance to PARP inhibitor therapy, at
least in the ex vivo setting [40]. Defective NHEJ may be
conferred by a wide range of molecular aberrations af-
fecting either the classical or the alternative pathways. In
general, molecular events can either be in the germline,
conferring an altered risk of developing the disease, or
somatic, implying that the genomic event is affecting cell
survival and subsequent sensitivity to therapy.
Classical pathway components
DNA-PK complex DNA-PK is the complex made up of
DNA-PKcs, Ku70/Ku80. Molecular study of platinum re-
sistant ovarian cancer has shown that DNA-PK is re-
sponsible for phosphorylating AKT at S743 and
relocating it to the nucleus. High expression of
DNA-PKCS is a common finding in high grade serous
cancer and associates with advanced stage, higher grade
and poorer survival due to reduced platinum sensitivity
[41]. PARP-1 has been shown to interact with Ku pro-
tein [42]. Genetic ablation of KU70 and LIG IV has been
shown to restore survival of PARP-1 deficient cells ex-
posed to DSBs inducing agents [43]. Also, DNA-PK
inhibition and depletion has been shown to result in HR
function recovery and PARPi resistance in vitro [44].
DNA LIG iv
Single nucleotide polymorphisms have been associated
with an increased risk of developing ovarian cancer [45]
although this remains controversial [46]. It is possible
that LIG IV variants result in dysfunctional NHEJ with
an associated hypersensitivity to DNA damage [33].
Alternative pathway components
Pol Θ Pol Θ is thought to promote A-EJ. Pol Θ expres-
sion has been found to be inversely proportional to HR
competency in epithelial ovarian cells in vitro and in-
creased expression has been found in serous ovarian
cancer [47].
XRCC1 Although often thought of as a protein whose
role is limited to NER, XRCC1 is relatively promiscuous
and appears to have functional roles in both the base
excision repair (BER) and non homologous end join-
ing pathways. Deficiency in XRCC1 can result in cell
death due to genomic stress, but can also allow for
accumulation of mutations, as SSBs remain unre-
paired. In ovarian cancer patients XRCC1 polymor-
phisms are associated with poorer prognosis and
higher levels of platinum resistance [48].
Pre-clinical studies of cells deficient in XRCC1 show
that these cells have higher sensitivity to platinum
chemotherapy than controls [49]. This is supported by
clinical data suggesting that EOC tumours overexpress-
ing XRCC1 and were more likely to be high grade serous
cancer, demonstrate platinum resistance, increased risk
of death and increased risk of tumour progression [49].
Implications for therapy
PARP inhibitors
Knowledge of NHEJ status may allow further enrich-
ment of a population that is likely to have a high re-
sponse rate to PARPi therapy.
DSB are repaired by the dominant, but more error
prone NHEJ pathway. Only if cells are NHEJ defective
(classical pathway) will DSB will be repaired by HR. Re-
cent data suggest that cells which are NHEJ defective de-
velop upregulated HR, as evidenced by increased RAD51
foci formation and are resistant to rucaparib [40]. How-
ever cells which are HR defective are still sensitive to
PARPi, as the alternative, PARP dependent pathway is
also inhibited.
DNA-PK
It is now becoming clear that platinum resistant clones
may be present in the primary tumour and can be selected
for, inadvertently, through the use of platinum based
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chemotherapy [50]. Platinum resistant high grade serous
EOC are associated with phosphorylated AKT, relocated
to the nucleus. By inhibiting DNA-PK or inhibiting AKT,
platinum sensitivity can be restored in cells rendered pre-
viously resistant [51].
Preclinical studies have found that treatment of malig-
nant ovarian cell lines with the combination of an EGFR
inhibitor, Gefitinib, plus cisplatin is able to reduce
DNA-PK expression, even in cisplatin resistant cells
[52]. Cisplatin has also been reported to inhibit NHEJ in
vitro [53]. Unravelling intracellular signalling properties
of already established drugs may be a rewarding avenue
in the future management of high grade serous ovarian
cancer.
The finding that Wortmannin, a member of the
DNA-PK family which inhibits PIKK, and is a radiosen-
sitiser in preclinical models, [54] led to the investigation
of other DNA-PK inhibitors as potential targets such as
Nu7441, a small molecule DNA-PK inhibitor found to
sensitise HeLa cells to ionising radiation and etoposide
[55, 56]in colon cancer. There are other small molecular
DNA-PK inhibitors, however none are yet reported to
have shown activity to high grade serous ovarian cancer.
XRCC1
XRCC1 expression has been suggested as a predictive
biomarker in human ovarian cancer with expression be-
ing associated with platinum resistance, suggesting that
XRCC1 positive tumours should be considered for non
platinum based chemotherapy [49].
Furthermore, XRCC1 may be a target for synthetic le-
thality, it is active in multiple DNA repair pathways,
with important activity in single strand repair pathways,
meaning that cells deficient in XRCC1 have higher reli-
ance on DSB repair pathways to maintain genomic in-
tegrity. Pre-clinical data, albeit regarding breast cancer,
has examined the synthetic lethality of inhibiting path-
ways for DSB in cells deficient in XRCC1 and found that
potent ATM and DNA-PKc inhibitors are synthetically
lethal in XRCC1 deficient cells [57].
Base excision repair
Mechanism of base excision repair
Base excision repair (BER) is responsible for both remov-
ing small base lesions from DNA and also effecting SSB
repair (via a subpathway of BER called single strand break
repair (SSBR)). Bases may become damaged due to react-
ive oxygen species (ROS), spontaneous deamination or
due to alkylation [58]. Single strand breaks (SSBs) are the
commonest endogenous DNA lesion. They arise from
DNA damage due to reactive oxygen species (ROS) or via
BER when damaged bases are excised [59].
BER repairs lesions generated endogenously by aerobic
respiration, but also therapeutically by ionising radiation,
topoisomerase I agents and DNA methylating agents.
BER can work by repairing one nucleotide in the pre-
dominant, short patch BER (SP-BER)pathway or by re-
placing 2–12 nucleotides as a long patch BER (LP-BER)
[58] (Fig. 3).
Role in high grade serous epithelial ovarian Cancer
The extent to which defective BER plays a role in high
grade serous epithelial ovarian cancer is not well identi-
fied, probably because of the difficulty of studying this
pathway independently of other DNA repair pathways.
However, there are some studies identifying how the
components of BER may contribute to ovarian cancer.
Polymorphisms of other BER components, notably the
glycosidase OGG1, result in an increased risk of ovarian
cancer, especially in women who are BRCA1 deficient
[60], and are a common finding with up to 63% of women
with ovarian cancer carrying these germline variants [61].
DNA polymerase activity upregulates the error prone
BER pathway, via pol β overexpression, in up to 67% of
ovarian cancers. Subsequent silencing of pol β induces
sensitivity to platinum chemotherapy, thus implicating pol
β in the low fidelity DNA repair mechanism which allows
cells to escape apoptosis by bypassing DNA lesions [62].
High nuclear expression of APE1 is associated with
high grade serous epithelial ovarian cancer and corre-
lates with poor surgical outcome, a poor overall survival
and possibly higher rates of platinum resistance when
compared to APE1 negative patients [63].
Implications for therapy
BER has the capacity to repair DNA which has been
intentionally damaged by therapy such as IR and alkylat-
ing agents. Therefore, by undermining BER whilst man-
aging patients with IR and chemotherapy, the effects can
be potentiated.
PARP inhibitors
PARP recruits and activates DNA repair proteins by
causing the post translational modification, poly
ADP-ribosylation. PARP1 has a key role in SSBR, as it
binds at single strand breaks, stabilising the DNA ends
and recruiting downstream proteins such as XRCC1. In-
hibition of PARP has been found to sensitize ovarian
cancer cells to chemotherapy because when PARP is
inhibited, BER cannot proceed and the SSB causes repli-
cation fork collapse when it is met in S phase, resulting
in DSB [64, 65], If the DSB cannot be repaired, then the
cell dies. As previously mentioned, PARP inhibition is
synthetically lethal in women with known defective
homologous recombination. Olaparib is being investi-
gated in clinical trials, not only as a monotherapy
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(clinicaltrials.gov identifier: NCT01844986) but also in
combination with AZD1775, a cell cycle checkpoint in-
hibitor (clinicaltrial.gov identifier NCT02511795), [66].
Pol β
Pol β has been identified as a potential target for inhib-
ition which would result in abrogation of BER and prevent
the tumour cell from withstanding oncogenic stress. One
inhibitor, masticadienomic acid (MA) has been identified
as a potent and selective Pol β inhibitor, which competes
for the active site of Pol β in ovarian cancer cell lines and
sensitises the cells to cis-platin [67]. Additional in vitro
studies have found Pol β inhibitors able to cause sensitisa-
tion to bleomycin and ionising radiation [68, 69].
APE1 inhibitors (APEX1)
In vitro studies of silencing APE1 using siRNA rendered
ovarian cancer cell lines sensitive to cisplatin and re-
sulted in cell apoptosis [70].Methoxyamine has been
found to inhibit APE1 in other cancers and studies of
methoxyamine in ovarian cancer cell lines have found it
to increase sensitivity to alkylatortemozolmide [71, 72].
There are multiple ongoing clinical trials of methoxya-
mine in various advanced or relapsed solid tumours, in-
cluding ovarian cancer (clinicaltrials.gov identifiers
NCT02535312, NCT01851369).
Mismatch repair
Mechanism of mismatch repair
Mismatch repair (MMR) is a mechanism for repairing in-
correct base matches and insertion/deletion errors gener-
ated during replication. Defects in MMR are associated
with genome instability due to higher rates of spontaneous
mutation and thus high levels of microsatellite instability
(MSI). MMR plays an instrumental role in DNA repair
but is also required for effective cell cycle arrest and apop-
tosis in severely damaged cells [73]. Hence, defective
MMR results in a predisposition to certain cancers and a
loss of sensitivity to chemotherapeutic agents.
Fig. 3 The Base Excision Repair Pathway. BER consists of 5 stages: Damaged bases are recognised and removed by BER glycolases to produce an
abasic intermediate. BER endonucleases (commonly APE1) make a site incision, generating a SSB. The sugar backbone is modified by phosphodiesterase.
The newly formed nucleotide gap is filled by DNA polymerase. DNA ligase seals the nucleotide patch together. In SP-BER DNA polymerase B
(Pol β) replaces the damaged nucleotide and the ends are ligated by DNA Lig III [58]. In LP-BER the patch is processed by proliferating cell nuclear
antigen (PCNA), 9–1-1 complex and flap endonuclease 1 (FEN1), the nucleotides replaced by Pol δ and Pol ε with ligation by Lig I. in the single strand
break repair (SSBR) pathway, PARP1 senses nicks in DNA, recruits XRCC1which acts as a scaffold for the other BER components to stabilise the SSB
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MMR has been extensively studied in E.coli, but is in-
completely defined in eukaryotic cells. MMR comprises 3
general stages, initiation, excision and resynthesis (Fig. 4).
MutS homologs (MSK2, MSH3, MSH6) recognise and
bind to mismatches and loops caused by the insertion/
deletion of up to 4 bases to form the hMutα or hMutβ
heterodimer complex. This occurs as hMutLα stabilises
the bind and distinguishes the newly formed, mutated,
DNA by scanning DNA for SSB or ‘nicks’. Nicks are
present transiently in newly synthesised lagging strand
DNA, before DNA ligase seals them, so nicks are the
eukaryotic method for distinguishing new DNA from
template DNA. The next stages are incompletely under-
stood in eukaryotes, but overall, DNA is then unwound
by a helicase and excised by exonuclease I (Exo I), this is
followed by resynthesis by polymeraseδ and ligation by
DNA ligase I, with the aid of the DNA sliding clamp,
proliferating cell nuclear antigen (PCNA).
Induction of cell apoptosis using MMR machinery is
hypothesised to happen by one of two possible mecha-
nisms (futile repair mechanism or the direct signalling
model), which both result in the recruitment of AMT/
ATR by hMutSα and hMutLα.
Role of mismatch repair in high grade serous epithelial
ovarian cancer
Microsatellite instability occurs when there are variable
lengths of unrepaired nucleotide repeats, MSI is used as
a marker for defective MMR in studies to determine the
frequency and contribution of defective MMR to cancer
development.
Defective MMR is understood to be a driver in Lynch
Syndrome, an autosomal dominant syndrome where indi-
viduals are predisposed to colorectal, endometrial and
ovarian cancers. The study of Lynch Syndrome, like other
hereditary cancer syndromes, has allowed a better under-
standing of the role of MMR proteins in cancer (Table 2).
Lynch Syndrome confers a 10–15% lifetime ovarian can-
cer risk, with ovarian cancer occurring at a younger age.
In contrast to BRCA1 and 2 mutations, the Lynch Syn-
drome phenotype predisposes to low grade [74] or clear
cell histology [75]. A large study of 2222 ovarian cancer
cases found that defective MMR contributed to only
0.18% cases of high grade serous ovarian cancer [76].
MMR is defective in sporadic ovarian cancer also,
where promotor methylation results in epigenetic silen-
cing of key genes (Table 2). The main proteins defective
in Lynch Syndrome are MHLH1 and MSH6.
Implications for therapy
In vitro studies have found an association between MMR
deficiency and resistance to platinum agents and DNA
methylating agents such as 6-thioguanine, due to an in-
activation of MMR driven apoptosis in ovarian cancer cell
lines [77, 78]. The extent to which defective MMR con-
tributes to therapy resistance in vivo, however, is inconclu-
sive [79] for high grade serous ovarian cancer, but is better
defined in ovarian clear cell carcinoma where defective
MMR plays a larger role in oncogenesis [80]. Nonetheless,
reactivation of MMR by demethylation of epigenetically
silenced MMR genes is an interesting area of study. In
vitro and mice studies, 5-azacytidine and 2′-deoxy-5-aza-
cytidine (DAC or decitabine) have been found to reacti-
vate MMR by demethylating the mMLH1 promoter,
resulting in the return of sensitivity to platinum therapies,
temozolomide and epirubicin [81, 82]. However, phase II
clinical trials using decitabine with carboplatin in ovarian
Fig. 4 Eukaryotic mismatch repair mechanism. DNA mismatches are recognised by the mismatch recognition factor MutSα, which then prompts
binding and DNA stabilisation by the MLH1-PMS2 heterodimer (MutLα). The PCNA and RFA clamp loader are able to load on at a nearby ‘nick’.
MutSα activated exonuclease 1 (Exo1) excise the mismatch in a 5′ to 3′ direction and the excised fragment of DNA is removed by the DNA
polymerase δ holoenzyme. DNA polymerase δ refills the DNA gap and it is ligated by DNA ligase I
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cancer were abandoned due to a lack of efficacy and the
development of adverse reactions (DACROC study).
Nucleotide excision repair
Mechanism of nucleotide excision repair
Nucleotide excision repair (NER) is a highly conserved
and versatile pathway used to remove ‘bulky lesions’
caused by UV light and carcinogens such as benzopyr-
ene, which would otherwise distort the DNA double
helix. Large protein complexes scan the DNA and iden-
tify distortions at the bulky lesion. Lesions that stall
transcription use the ‘transcription coupled NER path-
way’ using RNA Pol II. The ‘global NER pathway’ man-
ages lesions elsewhere affecting the genome. The
transcription factor, TF11H, has helicase activity and is
recruited to unwind the DNA duplex. XPG and
ERCC1-XPF then cleave the abnormal strand either side
of the lesion and DNA polymeraseδ or ε and ligase
3(LIG III) repair the gap with PCNA and replication fac-
tors C [59].
Defective NER is implicated in various cancers, not-
ably the syndrome xerodermapigmentosa which is char-
acterised by UV sensitivity, where global NER is
defective. Epigenetic alterations, gene polymorphisms
and SNP’s of global NER proteins are associated with
lung, skin and bladder cancer.
Role of NER in high grade serous ovarian cancer
NER is responsible for repairing intrastrand DNA cross
links caused by platinum therapy and has been found to
determine platinum resistance in ovarian cancer cells
in vitro [83, 84]. The TCGA data set analysis revealed
that 8% of high-grade serous EOCs have an NER gene
alternation which included homozygous deletions of
NER genes and nonsynonymous or splice site mutations.
The extent to which polymorphisms of NER genes and
their subsequent protein expression plays a role in the
platinum resistance of ovarian cancer is controversial,
with some studies finding direct correlation between
protein levels to platinum resistance and other studies
finding no correlation, (see Table 3) [85, 86]. However,
Ceccaldi et al.’s extensive TCGA study demonstrated
that NER gene alterations in high grade serous EOCs
were associated improved overall and progression-free
survival compared to tumours that did not have NER al-
terations. Specifically, two NER mutations; ERCC6-Q524
and ERCC4-A583T were functionally associated with
platinum sensitivity in vitro.
In the same study the survival of patients with tu-
mours harbouring NER alterations was similar to pa-
tients with BRCA1/2-altered tumours suggesting that
NER pathway alterations may contribute to EOC plat-
inum sensitivity to a similar extend as that of the effect
of BRCA1/2 loss. Ceccaldi’s data reported that NER
pathway alterations, unlike BRCA1/2 alterations, were
not associated with sensitivity to PARP inhibitors. Im-
portantly, their findings identified a subset of
NER-deficient, HR-competent EOCs with distinct plat-
inum and PARP-inhibitor profiles [87].
An interesting study by Wang et al. looked at the roles
of both NER and HRR in platinum resistance. They
found that the importance of NER’s contribution to plat-
inum resistance varies between in vitro cell lines. Add-
itionally, overall there was no correlation between NER
protein component expression and NER activity, nor cis-
platin sensitivity [88]. Yet, they did highlight that
ERCC1, the role of which is extensively studied in NER
and platinum resistance, also plays an influential role in
HRR. Delineation of the NER and HRR pathways in
these cells will be important when developing DNA re-
pair pathway modulators.
Implications for therapy
Development of NER inhibitors is a potential target for
the management of platinum resistant ovarian cancer.
There are a number of small molecular inhibitors, iden-
tified through in silico screens, with variable clinical
potential.
One promising agent is Trabectedin, which is thought
to disrupt the NER pathway by binding NER machinery
and DNA at the damaged DNA site, sequestering NER
proteins and resulting in cytotoxic complexes [83, 89].
Table 2 Defective MMR proteins in ovarian cancer
Gene/Protein Role Defect Clinical Effect Evidence of mutation
in cases of HGS
MLH1 Forms MutLα with PMS2 [95]
which has endonuclease activity.
Promoter methylation Spontaneous tumours 0.1%
Exon deletion Lynch Syndrome
MSH6 Forms hMutSβ with MSH2 to
recognise and initiate repair [95]
Exon deletion Lynch Syndrome 0.45%
MSH2 Forms hMutSβ 0.18%
PMS2 Forms MutLα Loss 0.05%
MutLα and MutSβ Recruit ATM/ATR Loss Resistance to DNA methylating
agents [77]
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The INOVATYON study is a phase III trial investigating
Trabectedin and pegylated liposomal doxorubicin (PLD)
vs carboplatin and PLD in women with platinum resistant
ovarian cancer(clinicaltrials.gov identifier NCT01379989).
The importance of developing a DDR stratification system
Targeting functional and dysfunctional DNA repair path-
ways in ovarian cancer, to overcome therapeutic resist-
ance is a frontier for improving the prognosis of ovarian
cancer. However multiple challenges exist. Firstly, clini-
cians require a way of identifying which DNA pathways
are important in a particular tumour. Secondly, an un-
derstanding of the interactions and overlap between the
pathways will be key to accurately targeting therapy.
Thirdly, although there are numerous small molecular
DNA repair pathway modulators which appear promis-
ing at a pre-clinical stage these need to be rapidly trans-
lated through clinical development.
The first two issues may be overcome through the de-
velopment and use of functional assays to either identify
key DNA repair pathways or identify key DNA repair
proteins (‘key drivers’), which may interact across nu-
merous pathways.
Importantly however, determining the DDR status of
any given HGSOC cancer is not trivial. Despite multiple
attempts to an assay for HR an ideal test remains elu-
sive. While BRCA-mutated cancers display a distinctive
gene expression signature, this in itself is not necessarily
predictive. In a recent study, 11 out of 12 tumours with
dominant BRCA signatures were refractory to primary
treatment, consistent with intact HR [84]. Furthermore,
attempts to use indirect methods such as genomic scar-
ring have been equally ineffective within the context of
clinical trials [21].
Studies to identify HR proficiency using the identifica-
tion of Rad51 focus formation in primary cultures, gath-
ered from ascitic fluid in women with ovarian cancer have
shown a promising way of identifying women with HR de-
ficiency who are susceptible to PARP inhibition [85]. Simi-
lar functional assays have been developed for the
assessment of NHEJ and NER status [86]. Development of
these assays further, for clinical use, may prove useful in
selecting women for targeted therapy via identification of
their DNA repair status.
If we know that a drug targets a specific protein in a
specific DNA repair pathway, then assessing function of
that protein represents an important biomarker. This can
be carried out by assessing the DNA, RNA or protein dir-
ectly. Immunohistochemistry of tissue samples can be
used to screen for key proteins and stratify patients into
groups likely to respond to the drug. Early work using im-
munohistochemistry and RT-PCR to identify DNA-PK/
mRNA in solid tissue as a predictor for NHEJ and correl-
ation with sensitivity to PARPi and cisplatin sensitivity is
one such promising example of this [90].
Conclusions
With the increasing realisation that ovarian cancer is not
one disease, the increased use of molecular diagnostics,
and the development of new targeted agents the ability
to deliver personalised medicine for patients with ovar-
ian cancer is perhaps finally on the horizon.
An understanding of the DNA damage repair path-
ways and how they are abrogated will allow the develop-
ment of personalised treatment algorithms but as we
have outlined here this is likely to be complex given the
high degree of interaction, overlap and perhaps redun-
dancy that is shown between the various pathways.
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Table 3 NER components and response to platinum therapy in ovarian cancer
Protein Role Relevant to Ovarian Cancer
ERCC1 Forms heterodimer with ERCC4 to form XPF, which
binds DNA with nuclease activity
SNP C8092A, which affects mRNA stability associated with reduced tumour size and
more differentiation [96].
In vitro cell line experiments found high ERCC1 expression correlated to platinum
resistance due to upregulated NER [97]
XPA Binds and stabilises damaged DNA Paradoxically XPA expression associated with better overall survival in women with
metastatic ovarian cancer and chemotherapy response [98]
XPB A transcription factor that can also aid unwinding
of DNA at sites of damage
Five fold higher mRNA expression in platinum resistant ovarian cancer cell lines than
non resistant cells [89].
XPG Endonuclease that catalyses 3′ incision No statistically significant effect of XPG polymorphisms [94]
CSB ATP dependent helicase that enables DNA repair Six times higher mRNA expression in platinum resistant ovarian cancer cells [98]
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